CSIMarket
 
Deciphera Pharmaceuticals Inc   (DCPH)
Other Ticker:  
 
 
Price: $15.5900 $-0.32 -2.011%
Day's High: $16.49 Week Perf: -5.74 %
Day's Low: $ 15.55 30 Day Perf: 2.03 %
Volume (M): 1,597 52 Wk High: $ 17.73
Volume (M$): $ 24,893 52 Wk Avg: $14.05
Open: $15.83 52 Wk Low: $9.90



 Market Capitalization (Millions $) 1,327
 Shares Outstanding (Millions) 85
 Employees 288
 Revenues (TTM) (Millions $) 163
 Net Income (TTM) (Millions $) -195
 Cash Flow (TTM) (Millions $) 18
 Capital Exp. (TTM) (Millions $) 1

Deciphera Pharmaceuticals Inc
Deciphera Pharmaceuticals Inc is a biopharmaceutical company that is focused on discovering, developing, and commercializing kinase inhibitor therapies for the treatment of patients with cancer. The company was established in 2003 and is based in Waltham, Massachusetts.

The core technology of Deciphera Pharmaceuticals is its proprietary kinase switch control inhibitor platform (KSCI). This technology enables the company to design highly selective inhibitors that target specific kinases and to optimize the molecules with respect to potency, safety, and pharmacokinetics.

The company's lead product candidate is Ripretinib (DCC-2618), an inhibitor of KIT and PDGFRe kinases that is being evaluated for the treatment of patients with gastrointestinal stromal tumors (GISTs). GISTs are rare cancerous tumors that arise in the digestive tract and account for approximately 1% of all gastrointestinal tumors.

In addition to Ripretinib, Deciphera Pharmaceuticals has a pipeline of early-stage product candidates that are being developed for the treatment of a variety of solid tumor indications. These include inhibitors of kinases such as FGFR, CSF1R, and VEGFR.

Deciphera Pharmaceuticals has collaborated with several pharmaceutical companies, including Eli Lilly and Company, Sanofi, and Takeda Pharmaceutical Company Limited, to develop and commercialize its product candidates. The company has also entered into licensing agreements with other companies to further develop its KSCI platform and expand its product portfolio.

The company has received several awards and recognitions for its innovative technology and drug development efforts. In 2019, Deciphera Pharmaceuticals was named one of the top 50 most innovative companies in the world by Fast Company. The company is also listed on the NASDAQ Global Select Market under the ticker symbol "DCPH."


   Company Address: 200 Smith Street Waltham 2451 MA
   Company Phone Number: 209-6400   Stock Exchange / Ticker: NASDAQ DCPH
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Deciphera Pharmaceuticals Inc

Headline: Deciphera Pharmaceuticals Inc Reports Surge in Revenue, However Struggles with Profitability in Q4 of 2023

Deciphera Pharmaceuticals Inc (DCPH) is a biopharmaceutical company that focuses on discovering, developing, and commercializing innovative medicines to improve the lives of people with cancer. The company recently announced its financial results for the fourth quarter and year ended December 31, 2023.
In the fourth quarter of 2023, Deciphera Pharmaceuticals reported a net loss of $-47.190 million, which was larger than the net loss of $-45.935 million in the same period a year ago. However, the company's revenue surged by 32.877% to $48.29 million from the previous year's reporting season. This growth in revenue is positive compared to its industry peers, who experienced an average business rise of only 0.52% during the same period.

Product Service News

Deciphera Pharmaceuticals Champions Hope for GIST Patients with Revolutionary Study Results

Published Thu, Jan 18 2024 4:13 PM UTC

WALTHAM, Mass. - Deciphera Pharmaceuticals, a renowned biopharmaceutical company dedicated to the development of groundbreaking cancer treatments, has recently announced the release of long-term findings from the INTRIGUE Phase 3 clinical study. These results shed light on the efficacy of QINLOCK (ripretinib) in comparison to sunitinib for patients with advanced gastrointest...

Contract

GENESIS Pharma's Exclusive Distribution Agreement with Deciphera Pharmaceuticals Fuels Growth in Central and Eastern Europe

Published Fri, Jan 12 2024 3:56 PM UTC

In a significant development, GENESIS Pharma, a renowned regional biopharmaceutical company operating in Europe, has recently entered into an exclusive distribution agreement with Deciphera Pharmaceuticals, Inc. The agreement involves the marketing of RIPRETINIB, a groundbreaking medication designed to improve the lives of cancer patients, across 14 markets in Central and Ea...

Business Update

Deciphera Pharmaceuticals Outlines Ambitious 2024 Goals and Achievements, Sets Path Towards Self-Sustainability

Published Mon, Jan 8 2024 12:00 PM UTC

Massachusetts-based biopharmaceutical company, Deciphera Pharmaceuticals, recently unveiled its strategic outlook for 2024 and disclosed preliminary unaudited fourth quarter and full year 2023 revenue figures. These announcements not only shed light on the company's progress but also underline its commitment to developing and commercializing groundbreaking medicines that can...

Product Service News

Deciphera Announces Important Clinical Breakthrough: QINLOCK Shows Remarkable Benefits in GIST Patients

Published Fri, Jan 5 2024 12:00 PM UTC

Deciphera Pharmaceuticals, a formidable player in the biopharmaceutical domain, continues to leave an indelible impact in the global fight against cancer. It recently announced a significant accomplishment - Nature Medicine's publication of the results derived from a key ctDNA (circulating tumor DNA) analysis from its pivotal INTRIGUE Phase 3 study. This critical research fo...






 

Deciphera Pharmaceuticals Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Deciphera Pharmaceuticals Inc does not provide revenue guidance.

Earnings Outlook
Deciphera Pharmaceuticals Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com